ALGARROBO



Botanical name:
Prosopis pallida (huarango / Peruvian algarrobo). Not P. denudans. Not Ceratonia siliqua.
Alternative names:
Huarango, algarrobo, algarrobina (syrup), kiawe (Pacific P. pallida)
Main indications:
food and everyday energy (pods, algarrobina)
loose stool and a tender stomach, in folk use
cough and chest tightness (syrup), in folk use
convalescence as food, not a drug
Short characteristics:
Huarango is Prosopis pallida, a coastal dry-forest tree of northern Peru. People eat the sweet pods and boil them into algarrobina, a dark syrup for drinks and desserts. Spaniards named it for Mediterranean carob. They are not the same plant. It is also not Patagonian P. denudans.
Kitchen medicine: pulp for loose stool, syrup for a cough, leaf or sap poultice. That is food, not oncology or neurology. Older copy mixed carob nutrition studies with lung-cancer and childhood-paralysis lines. Those claims do not belong here.
This site sells nothing.
The usual way of use:
Food amounts: up to 30 g powder a day for adults, up to 15 g for children. Poultice of leaf or sap is folk topical use.
This site sells nothing.
WARNING: Tannin-rich pods in excess can interfere with iron and protein absorption. Not a lung-cancer or paralysis medicine. Fabaceae allergy is possible.
Composition
Sweet pod sugars, fiber, tannins, and C-glycosyl flavones in the syrup. Bark is astringent. Do not paste Mediterranean carob tables onto this tree.
Traditional use
Coastal Peruvian food: flour, algarrobina, a cough syrup in the kitchen, pulp for diarrhea, leaf poultice. No formula membership on this site.
Precautions
Tannins, Fabaceae allergy, iron absorption if you live on the powder. Do not swap in carob or P. denudans papers.
Opened studies
Henciya et al. (2017). Prosopis genus review. Journal of Food and Drug Analysis. Genus-only; not a P. pallida disease trial. PMID 28911536 · doi:10.1016/j.jfda.2016.11.001.
Bohórquez-Medina et al. (2025). Peruvian Prosopis pallida as food (algarrobina). Journal of Ethnic Foods. Food paper; no human disease trials. doi:10.1186/s42779-025-00270-w.